Dr. Ewelina Kulikowski reports

RESVERLOGIX ANNOUNCES NEW INSIGHTS INTO THE MECHANISM OF APABETALONE'S CARDIOPROTECTIVE BENEFIT IN CHRONIC KIDNEY DISEASE PATIENTS

A peer-reviewed article, entitled, "Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment," by Resverlogix Corp.'s Dr. Dean Gilham and colleagues, has been published in Biomedicines, a prestigious scientific journal. The article explores the favourable impact of apabetalone treatment on kidney cells and its implications for the prevention of negative cardiovascular outcomes in people suffering from chronic kidney disease (CKD).

Publication highlights include:

• Loss of kidney function is an independent risk factor for cardiovascular disease, as cardiovascular events are the leading cause of death in CKD patients.
• In the phase 3 BETonMACE trial, apabetalone reduced risk of major adverse cardiac events (MACE) by an extraordinary 50 per cent among participants with reduced kidney function.
• In this study, activated human kidney cells were treated with apabetalone to investigate its impact on disease associated pathways and processes.
• Apabetalone treatment suppressed the expression of key drivers of fibrosis, inflammation and calcification, all of which contribute to development and progression of CKD, and negatively impact the kidney-heart axis.
• These findings were confirmed by proteomic analysis of blood samples taken from CKD patients treated with apabetalone.

"We saw, in BETonMACE, that apabetalone treatment improved cardiovascular outcomes in patients with reduced kidney function," said Dr. Ewelina Kulikowski, chief scientific officer at Resverlogix. "This study provides insight into the underlying mechanisms that contribute to this positive outcome."

Additionally, Resverlogix announced today its participation in the coming scientific conference hosted by the European Renal Association in Milan, Italy. A poster, entitled "Apabetalone Reduces Cardiac Events in CKD Patients by Downregulating Fibrotic and Inflammatory Processes," will be presented by BETonMACE clinical steering committee member and UCLA nephrologist, Dr. Kam Kalantar-Zadeh, on Friday, June 16, 2023, at 8:30 a.m. (CET).

About apabetalone

Apabetalone (RVX-208) is a first-in-class, small-molecule therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extraterminal) inhibitor that works in preventing and treating disease by regulating the expression of disease-causing genes.

Due to the extensive role for BET proteins in the human body, apabetalone can simultaneously target multiple disease-related biological processes representing to a new way to treat chronic disease. Apabetalone is the only drug of its class that is well tolerated for chronic administration, with an established safety record in human clinical trials, including over 4,200 patient-years of safety data across 10 trials.

Cardiology

Apabetalone is the first therapy of its kind to receive breakthrough therapy designation from the U.S. Food and Drug Administration for a major cardiovascular indication following the groundbreaking findings from its phase 3 study, BETonMACE. Data from this trial showed apabetalone may prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have Type 2 diabetes mellitus.

About Resverlogix Corp.

Founded in 2001, Resverlogix is a Calgary-based late-stage biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. It aims to improve patients' lives by restoring biological functions -- altered by serious illnesses such as cardiovascular disease -- back to a healthier state.

The company's clinical program is focused on evaluating the lead epigenetic candidate, apabetalone, for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions.

Resverlogix has partnered with Eversana, the pioneer of next-generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

We seek Safe Harbor.